04Sep 2023
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis

A study assessed the interchangeability of adalimumab biosimilar PF-06410293 (adalimumab-afzb) and reference adalimumab, aiming to increase access to effective treatment. The study involved 445 patients across ten countries and found no significant differences in pharmacokinetics, safety, or efficacy between the biosimilar and reference adalimumab. This suggests that multiple switches between the two are as safe and effective as using reference adalimumab alone, potentially expanding treatment options for rheumatoid arthritis patients.

  • #rheumatology

Like

Save

Share